Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
- Previous Close
0.4180 - Open
0.3860 - Bid 0.2800 x 200
- Ask 0.5382 x 200
- Day's Range
0.3860 - 0.4140 - 52 Week Range
0.3500 - 2.7500 - Volume
10,583 - Avg. Volume
43,714 - Market Cap (intraday)
6.962M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
www.shuttlepharma.com8
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SHPH
Performance Overview: SHPH
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SHPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SHPH
Valuation Measures
Market Cap
6.96M
Enterprise Value
2.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.72
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-50.43%
Return on Equity (ttm)
-112.37%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6.59M
Diluted EPS (ttm)
-0.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
5.46M
Total Debt/Equity (mrq)
26.82%
Levered Free Cash Flow (ttm)
-2.75M
Research Analysis: SHPH
Company Insights: SHPH
SHPH does not have Company Insights